Cardiovascular and Metabolic Effects of Drugs for the Treatment of Obesity
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Liraglutide (Primary) ; Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 25 Jul 2024 Results assessing growth/differentiation factor 15 (GDF-15) levels in response to antiobesity medications, namely, liraglutide (Lira) and naltrexone/bupropion (N/B), in individuals with overweight or obesity, published in the Diabetes, Obesity and Metabolism.
- 02 Jun 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified October 2020).
- 07 Oct 2020 New trial record